
Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit.
Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America.
With more than 1,600 employees and sales which exceeded 1.1 billion Euros in 2024, the company is one of the fastest-growing independent commercialization platforms for biopharma globally.
Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof.
For more information about Swixx, please visit: www.swixxbiopharma.com.
The Association of Medical Specialists for Risk Modification was established in 2021 to attract the attention of the medical community and the general public to solving the problems of managing modifiable risk factors in order to prevent, effective primary and secondary prevention, treatment and rehabilitation of chronic non-communicable diseases, other syndromes, conditions and injuries leading to a loss of autonomy, a decrease in the quality and life expectancy of citizens. The focus of the Association's activities is the development and implementation at the federal level of programs for the comprehensive improvement of the quality of life of patients through the modification of risk factors and the creation of long-term motivation to change consumer behavior. The Association strive to organize a dialogue between all participants in the risk modification process - regulators, doctors, patients, social workers, business representatives.
Alisa has over 20 years of experience in the pharmaceutical industry.
She worked at Roche for about 10 years in Marketing Department.
In 2012, Alisa joined Bristol-Myers Squibb as Project Manager for Immunology and Oncology in Market Access Department.
In 2014, she moved to the position of Regional Market Access Managers Head.
From 2017 to 2021, she held the position of Market Access and Pricing Department Director, during which time Alisa also had experience as Commercial Director and Acting General Director.
Since December 2021, she has been transferred to the position of Oncology Department Director.
In June 2022, Alisa joined Swixx Healthcare, as a Director of Oncology and Market Access Departments. Since January 2023, she has held the position of Deputy General Director.
Alisa graduated from the 1st Moscow State Medical University I.M. Sechenov, received a PhD in Pharmaceutical Sciences.